Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.
Guy Goodwin, MD
Advertisement
Dr Goodwin is the chief medical officer at Compass Pathways, as well as the Emeritus Professor of Psychiatry and NIHR Emeritus Senior Investigator at the University of Oxford, UK.
Articles by Guy Goodwin, MD
Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.
Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.
Compass Pathways reports COMP360 psilocybin shows fast, durable relief in treatment‑resistant depression. Guy Goodwin, MD, shares his insights.
How are MDMA and psilocybin reshaping PTSD and depression care? Learn more in our Psychedelics Special Report.
Learn more about the transformative potential of psychedelics in treating depression and mood disorders through expert insights and groundbreaking research.
Advertisement
Latest Updated Articles
Psychedelics: Powerful Tools for Burdensome DisordersFebruary 18th 2026
Advertisement
Advertisement
Trending on Psychiatric Times
1
Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
2
FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults
3
How Can Sleep Disruption Trigger Mood Episodes?
4
Evaluating Transdermal Asenapine in Schizophrenia
5